Drug Profile
Bisphosphonates subcutaneous - Halozyme
Alternative Names: Bisphosphonate-PH20; Recombinant human hyaluronidase/bisphosphonatesLatest Information Update: 29 Aug 2018
Price :
$50
*
At a glance
- Originator Halozyme Therapeutics
- Class Bisphosphonates; Glycoside hydrolases; Polysaccharide lyases; Recombinant proteins
- Mechanism of Action Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 15 Dec 2008 Phase-I clinical trials in Osteoporosis in USA (SC)